The latest research progress and indication expansion of selumetinib

In recent years, selumetinib (Selumetinib) has continued to make new progress in the treatment of neurofibromatosis (NF1). Following the 2020 approval by the FDA for the treatment of children with plexiform neurofibromas (PN), at the beginning of 2025, AstraZeneca has submitted a marketing application for selumetinib to the China National Food and Drug Administration for adult NF1 patients. This application is based on a number of international phase III clinical data, which shows that adult patients’ tumor volume was significantly reduced and symptoms were significantly relieved after using selumetinib, marking a substantial breakthrough in its indication expansion.

The latest clinical research points out that selumetinib also shows stable efficacy in adult NF1 patients. Data show that more than 60% of patients who received treatment saw their tumors shrink by more than 20% within 16 weeks, and some patients reported that symptoms such as pain and functional limitations also improved. More importantly, its adverse reactions are relatively controllable, mainly rash and mild diarrhea, and no serious systemic toxic reactions have occurred, which makes long-term maintenance treatment possible.

At present, in addition to the United States and Europe that have approved pediatric indications, Japan, Canada and other countries are also actively reviewing it. At the same time, the expansion of indications for adult NF1 patients has become a focus of regulatory agencies in many countries. In the Chinese market, if selumetinib can be successfully approved for adult indications, it will fill the gap in domestic adult NF1 drug treatment and is also expected to promote the upgrading of domestic NF1 treatment standards.

In addition to NF1, selumetinib is also exploring the possibility of being used in other RAS/MAPK pathway-related tumors, including KRAS mutated lung cancer, thyroid cancer, melanoma, etc. In these clinical studies, selumetinib was used in combination with other targeted drugs or immune drugs, and preliminary results showed synergistic anti-tumor potential. In the future, with the advancement of precision medicine, selumetinib is expected to further expand its indications and become an important treatment option for patients with various tumors.